CoChat

Probiotics and Intestinal Inflammatory Disorders in Infants and Children

Vanderhoof, Jon A. · 2000 · Journal of Pediatric Gastroenterology and Nutrition
Cited by 45

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

In the newborn infant, lifelong intestinal flora are typically acquired during the neonatal period. Consequently, the infant tends to acquire the flora swallowed from the vaginal fluid at the time of delivery (1,2). There may be some additional acquisition of flora early in life, but once it is established and immune tolerance to the organisms is achieved, intestinal flora remains relatively constant throughout life. Because vaginal flora and intestinal flora are similar, an infant's flora may closely mimic the intestinal flora of the mother. Infants born by Caesarean section commonly acquire and are colonized with flora from the hospital environment and, therefore, flora in these infants may differ from maternal flora (Table 1).TABLE 1: Infant microflora Attempts to modify intestinal flora originated through the feeding of live organisms in fermented food products (3). Since that time, a number of attempts have been made to alter or augment intestinal flora to achieve a positive clinical benefit or reduce the risk of potentially harmful conditions. The most obvious means would be the administration of live organisms or probiotics (4-7). These are micro-organisms that when ingested, may have a positive effect on the prevention or treatment of a specific pathologic condition. Traditionally, probiotics are organisms of human origin. Biotherapeutic agents are micro-organisms that are used for the treatment of a specific disease or illness (8). Saccharomyces boulardii is an example. Because it is not a normal human organism, it is often not considered a probiotic. Prebiotics are substances that, when ingested, promote growth and establish beneficial micro-organisms (9,10). Examples of prebiotics include fructose oligosaccharides and, in infants, lactose. They are often designed to promote the growth of bacteria, such as Bifidobacterium, because they thrive in a lower pH environment and may reduce colonization by more aggressive or invasive organisms. Any of these agents can be added to foods to form what is known as a "functional" food. Functional foods, therefore, alter human physiology in a meaningful way to produce some type of health benefit. A perfect example is yogurt, which may contain probiotic bacteria. Most probiotics are lactic acid bacteria (5). This is a large group of bacteria so named because they produce lactic acid as an end product of metabolism. Because there is much genetic diversity among lactic acid bacteria, very few of them have probiotic effects, and those that do differ markedly. This accounts for much of the inconsistency in data regarding the efficacy of probiotics. It is also the probable reason for the efficacy of some species of bacteria that work in some conditions but not in others. Lactic acid bacteria are commonly used as probiotics because of their long history of safety in food and dairy products and the absence of untoward effects over many years of experience (11). Mechanisms of probiotics include competition exclusion, colonization resistance, and immune modulation. There is considerable controversy and many gaps in the data in this regard. We know that bacteria that adhere to the intestinal epithelium are much more effective at colonizing the gastrointestinal tract, thereby giving them a distinct advantage as probiotics (3,5,6,12). Many bacteria, when ingested, are killed by gastric acid and bile; bacteria that survive exposure to gastric acid and bile have a distinct advantage as probiotics (13). Adhesion to the mucosal epithelium may competitively inhibit the attachment of more pathogenic organisms by a process known as competitive exclusion. Historically, this has been considered the main mechanism through which probiotics produce their therapeutic effect. However, there are probably many others. Some probiotic bacteria are known to produce chemical substances, or bacteriocins, that may kill or inactivate other bacterial species (14). Bacteria may also modulate the intestinal immune system or alter its targeting in a way that produces a positive clinical effect (15,16). Lactobacillus GG is perhaps the most studied probiotic bacterium. It is known to grow in bile and is relatively acid resistant, growing well in pH down to 3.0 (13,17). It has been shown to survive and grow in the intestinal tract based on fecal excretion data. It is a nonpathogenic organism in humans. It adheres tightly to intestinal mucosal cells in an in vitro model system and produces an antimicrobial substance that has been shown to inhibit the growth of micro-organisms. Probiotics have been shown to be useful in the treatment of a variety of disorders (Table 2). A number of these disorders have a significant inflammatory component in the small intestine or colon. Consequently, there is ample evidence to suggest that probiotic bacteria may be useful in the treatment of a number of conditions in which intestinal inflammation is present. Perhaps the greatest area of study thus far has been in diarrhe

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00005176-200000002-00006

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 45

Metadata

Authors
Vanderhoof, J. A.
Venue
Journal of Pediatric Gastroenterology and Nutrition
Publisher
Wiley
Published
2000
Volume
30
Pages
S34-S38
ISSN
0277-2116 (ISSN-L)
OpenAlex
W2061642054
Cited by
45
References
2
FWCI
8.86
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Probiotics and Intestinal Inflammatory Disorders in Infants and Children. https://app.cochat.ai/papers/10.1097/00005176-200000002-00006
The paper
Vanderhoof, J. A. (2000). Probiotics and Intestinal Inflammatory Disorders in Infants and Children. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1097/00005176-200000002-00006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.